Latest Compliance News

betr Entertainment has issued its first supplementary bidder’s statement reaffirming its takeover offer for PointsBet, rejecting MIXI’s competing bid and outlining key next steps including a selective buy-back and acceptance facility.

Perpetual Credit Income Trust reported a 20.7% increase in net assets to $532.8 million for FY25, while posting a modest profit decline amid challenging market conditions. The Trust’s $93 million capital raise and diversified credit portfolio underpin its strategy for stable income and growth.

Health and Plant Protein Group Limited (HPP) reported a reduced net loss of $528,000 for FY2025, following the receipt of final proceeds from its US divestment. The Board signals plans to return capital and pursue new corporate opportunities.

Xamble Group Limited has clarified that its recent share price surge is linked to a newly announced renounceable rights issue, dismissing speculation of undisclosed information.

AGL Energy has clarified that its FY25 underlying earnings aligned with market forecasts and published guidance, dismissing any material surprises in its financial results. The company also addressed statutory profit volatility and confirmed compliance with ASX disclosure rules.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

Cannindah Resources Limited has had its trading suspension lifted immediately following the release of a capital raising announcement, signaling renewed market activity.

The ASX has suspended the securities of 36 companies for failing to pay their annual listing fees by the August 21 deadline, with a looming delisting threat if fees remain unpaid by August 28.

Omnia Metals Group Limited has issued a prospectus to list up to 10,000 options, aiming to remove trading restrictions and facilitate secondary market activity. This move follows recent capital raisings and shareholder approvals, positioning the company for enhanced liquidity.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

Monash IVF Group reported a 5.6% rise in underlying EBITDA for FY25, navigating a declining Australian IVF market and operational challenges. The company sets a cautious FY26 NPAT guidance of $20-23 million while focusing on regaining market leadership and implementing safety reforms.

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.